Accueil>>Signaling Pathways>> Others>>KR-33493

KR-33493

Catalog No.GC19214

Le KR-33493 est un puissant inhibiteur de la mort cellulaire médiée par Fas (FAF1).

Products are for research use only. Not for human use. We do not sell to patients.

KR-33493 Chemical Structure

Cas No.: 1021497-97-1

Taille Prix Stock Qté
5mg
185,00 $US
En stock
10mg
278,00 $US
En stock
50mg
834,00 $US
En stock
100mg
1 298,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

KR-33493 is a potent inhibitor of Fas-mediated cell death (FAF1).

Body weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups of either sex are found in hematology, serum biochemistry, and urinalysis. In dogs administrated KR-33493 for 2 weeks, red blood cell count (RBC) value in males is significantly higher at the 1000 mg/kg/day dose than that of the control group (i.e., 6.96±0.323 vs. 6.12±0.418). However, the change of RBC is recovered after the end of the administration period. The dose-normalized AUClast is not significantly different between the groups, suggesting that KR-33493 is governed by linear kinetics[1].

References:
[1]. Jeong JW, et al. Subacute toxicity evaluation of KR-33493, FAF1 inhibitor for a new anti-parkinson's disease agent, after oral administration in rats and dogs. Regul Toxicol Pharmacol. 2016 Nov;81:387-396.

Avis

Review for KR-33493

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for KR-33493

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.